Skip to main content
An official website of the United States government

Pertuzumab (PERJETA®)

Agent Description

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. Pertuzumab has an approximate molecular weight of 148 kDa. Pertuzumab is a sterile, clear to slightly opalescent, colorless to pale brown liquid for intravenous infusion. Each single use vial contains 420 mg of pertuzumab at a concentration of 30 mg/mL in 20 mM L-histidine acetate (pH 6.0), 120 mM sucrose and 0.02% polysorbate 20.

Mechanism of Action

Pertuzumab targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It thereby blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signal pathways: mitogen-activated protein (MAP) kinase, 444 and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC). While pertuzumab alone inhibited the proliferation of human tumor cells, the combination of pertuzumab and trastuzumab augmented anti-tumor activity in HER2-overexpressing xenograft models.

Classification

Antineoplastic agent; monoclonal antibody

Molecular Target

HER2/neu

Monograph

Approved Indications

  • Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
  • Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall survival.

Limitations of Use

  • The safety of pertuzumab as part of a doxorubicin-containing regimen has not been established.
  • The safety of pertuzumab administered for greater than 6 cycles for early breast cancer has not been established.

View the pertuzumab package insert (PDF).

Studies of Interest

Areas NOT of Interest

  • Combinations with ado-trastuzumab emtansine
  • Combinations with bevacizumab
  • Combinations with biosimilar trastuzumab
  • Novel combinations in the absence of phase I data
  • Studies that are answering another company’s development or medical questions where pertuzumab plus trastuzumab is already standard of care

Information collaborator would like included in investigator proposals 

N/A

Genentech supports non-clinical research proposals through a separate mechanism. Please visit Genentech's Outgoing Material Transfer Agreement (MTA) Program to submit a request for a Genentech agent for non-clinical work.

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Pertuzumab (PERJETA®) was originally published by the National Cancer Institute.”

Email